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Introduction
Glycogen phosphorylase (GP), an enzyme that catalyzes the first step of intracellular degradation of glycogen to Glc-1-P 1 , has been an important target for the discovery of novel hypoglycaemic agents [1] [2] [3] [4] . The efficacy of such inhibitors on blood glucose control and hepatic glycogen balance has been confirmed from biological studies [5] [6] [7] [8] [9] . The main physiological inhibitor of GP is glucose, albeit a weak inhibitor (Ki= 2-3 mM). Inhibition of the catalytic site of the enzyme has therefore been probed with glucose based analogues 10 , designed on the basis of information derived from the crystal structure of the T-state GPb-α-D-glucose complex 11 . These inhibitors mainly have α-and β-substitutions at the anomeric C1 atom of the glucose moiety 2, 10 with the β-substitutions aiming to exploit the catalytic subsite called β-cavity, an empty space at the β-1-C configuration lined by both polar and non-polar groups. A key structural feature of glucose based ligands is the so called linker which connects the glucose moiety with an R group (Scheme 1). One such linker is the -NH-COgroup and has led to the identification of ligands in the μΜ range for GP inhibition when following the general reaction scheme shown in Scheme 2 2, 12 . Using this linker, however, only selected R groups have been previously studied towards exploiting the β-cavity features.
Hence in the current work we have adopted a more systematic approach and used a virtual screening methodology to discover new -R groups. Docking using both the Glide (CombiGlide) 13, 14 and GOLD 15 programs with different scoring functions was employed for this purpose, with the final ranking of ligand potencies based on a consensus scoring approach 16 combining the best performing scoring functions based on calculations for a training set of ligands. The diverse set of R groups for virtual screening was derived from acid chloride (RCOCl) molecules downloaded from the Zinc docking database 17 . Selected candidates from the virtual screening were then experimentally evaluated. Absorption, distribution, metabolism and excretion (ADME) property predictions from the QikProp program 14 allowing us to select a final set of beta-D-glucopyranose-NH-CO-R ligands with drug-like properties as a criterion for further evaluation 18, 19 . Thus, we also report here the synthesis of novel N-acyl-β-D-glucopyranosylamine type inhibitor series (S) shown in Table 1 and their biochemical and ex vivo assessment. We have determined the crystal structures of their complexes with GPb to analyze the molecular elements that govern molecular recognition by the catalytic site of the enzyme with emphasis in the β-pocket environment. The common kinetic and structural features of these compounds are that they are highly selective for GPb and they are competitive inhibitors with respect to the substrate Glc-1-P. They bind at the catalytic site and stabilise the T-state conformation (closed) of the 280s loop by making several favourable contacts with residues of this loop. Furthermore, compounds were designed to fill an empty pocket at the β-1-C configuration of glucose 20 , denoted as the β-channel, with bulky non-polar groups.
Three of the best N-acyl-β-D-glucopyranosylamines inhibitors of GP have been identified in this work (< 10 µM activity), which also have revealed promising activity in the cell in agreement with ADME predictions. The present work constitutes the first integrated structurebased drug design with high-throughput screening of commercially available small molecule libraries for glycogen phosphorylase inhibitors (GPIs). It also highlights the modeling perspective on GP and inhibitor and how calculations can support experiment in a more rational and time-efficient approach to design of potent, drug-like GPIs.
Materials and methods

Virtual Screening
Protein Preparation.
The GPb receptor structure was prepared for modeling using the 2.15 Å resolution GPb-N-4-phenylbenzoyl-2-N'-β-D-glycopyranosyl urea crystal complex (PDB ID: 2QLN). This receptor was chosen based on its previous performance in docking studies, its co-crystallized ligand having a bulkier R substituent which opens up the β-cavity in regions complementary to binding of the other ligands 4 
. Schrödinger's 'Protein Preparation
Wizard' 14 was used for the preparation with water molecules within 5 Å of the ligand initially retained, but deleted for subsequent docking. Bond orders were assigned and hydrogen atoms added, with protonation states for basic and acidic residues based on residue pKa's at normal pH (7.0). However, subsequent optimization of hydroxyl groups, histidine C/N atom "flips"
and protonation states, and side chain O/N atom "flips" of Asn and Gln residues was based on optimizing hydrogen bonding patterns, so that the final assignments were checked on visual inspection of the protein. In particular, all final His residues were assigned as neutral, either in a HIE or HID state. The PLP co-factor was used in its mono-anion form. Finally, the system was softly minimized using Impref and the OPLS-AA (2005) forcefield 21 with the root-meansquare deviation (RMSD) of heavy atoms kept within 0.3 Å of the crystallographic positions.
Ligand Preparation
The training set of 40 ligands (Table S1 ) was selected from previous studies 2, 22 with Ki values ranged from 0.35 µM to no inhibition. For consistency, a similar protocol for preparation of both the training and screening set ligands was used. In effect, the training set -R groups were first built as acid chlorides using Maestro and LigPrep.
The acid chlorides were then "reacted" at a β-D-glucopyranose-NH2 attachment point (-NH2) using modules from the combinatorial screening CombiGlide program of Schrodinger 14 in a manner that reflected the actual synthetic routine (Scheme 2). For the virtual screening set, the acid chloride molecules were downloaded in pre-determined low energy conformations (any relevant tautomers/ionization states included) from the Zinc database. To ensure that the final ligands were 'drug-like', the following criteria were used as filters: the structural pattern - effects. Positional constraints were applied on the hydroxyl (-OH) groups of glucose 23 . Glide standard (SP) and extra-precision (XP) modes were used.
GOLD Docking
In the docking calculations with GOLD 5.0 15 , all atoms and their associated residues within 10Å of the ligand were used to define the active site. The information about the ligand hydrogen-bonding interactions and conformation was encoded into the corresponding genetics algorithms (GA) of GOLD GoldScore, ChemScore, ASP and ChemPLP using the default GA parameters. Scaffold constraints were applied for the glucose ring atoms with weight 1.0 Å.
Consensus Scoring
In combining the results from individual docking methods, the ranks from the best performing scoring functions were added to give a rank-sum for each ligand, otherwise known as a Simple Sum Rank 16 .
Statistical Analysis of Docking Performance
For the training set, performance with respect to recovery of the actives (top 10 inhibitors) was analyzed in a statistical manner [24] [25] [26] [27] .
Since only a small fraction of a database is tested experimentally in practical VS studies, it is important to recognize actives or leads as "early" as possible. We therefore examined several metrics ranging from the commonly used hit rate and enrichment factor, to those that better highlight "early recognition". Hit-rate is the simplest metric and represented the % of actives in the predicted top 10 ligands for a particular docking method. The EF may be defined as the ratio of the number of actives retrieved relative to the number of database molecules tested.
An EF is often described with respect to a given percentage of the database screened. In general, if n represents the total number of actives and N represents the total number of molecules in the database, then if there are na actives among the Nx% molecules in the first x% of the database screened, the EF is given by Mackey and Melville
28
In our case we are looking at simply recovery of na =10 actives in a set of N=40 ligands, where x%=25% A ROC plot is conceptually similar to an enrichment plot and shows the relationship between the true positive rate (TPR, or sensitivity) and the false positive rate (FPR, or specificity) 29 . The Area Under the ROC curve (AU-ROC) is a common way to summarize the overall quality of a ROC plot.
where fi is the fraction of decoys or non-actives ranked higher than the ith active. The value of the AU-ROC varies between 0 and 1, where 1 represents a perfect ranking (all actives ranked above the decoys) while 0.5 corresponds to a random ranking. However, EF and AU-ROC values do not distinguish early and late performance. 24 Accordingly, we also used the metric "sum of logarithms of ranks" (SLR) which emphasizes on the "early recognition" of actives.
The SLR metric is calculated as:
where ri is the rank of the ith active. The negative logarithm emphasizes early recognition.
Noting that for an ideal case, a VS method would rank all actives within the first n positions, a theoretical maximum SLR may be calculated as:
This allows a normalized SLR (NSLR) to be calculated as:
This metric ranges from 0 to 1 (best achievable ranking). The result was grouping of the final 29 compounds into 15 families (Table S3) .
Screening Set
Chemistry
Thin layer chromatography (TLC) was performed on Merck precoated 60F254 plates.
Reactions were monitored by TLC on silica gel, with detection by UV light (254nm) or by charring with sulfuric acid. Flash column chromatography was performed using silica gel (240-400 mesh, Merck). 1 H and
13
C NMR spectra were obtained at room temperature with a
Bruker 400 spectrometer at 400 and 100 MHz, respectively using chloroform-d (CDCl3) and dimethylsulfoxide-d6 (DMSO-d6) with internal tetramethylsilane (TMS). Chemical shifts (δ)
were given in ppm measured downfield from TMS, and spin-spin coupling constants are in Hz. Mass spectra were obtained on a ThermoQuest Finnigan AQA Mass Spectrometer (electrospray ionization). Optical rotations were measured using an Autopol I polarimeter.
The IR spectra were obtained with a Thermo Scientific Nicolet IR100 FTIR spectrometer.
All coupling reactions were performed under an atmosphere of oxygen-free nitrogen, and the solvent (or solution) was vigorously deoxygenated with N2 prior to addition of catalysts. DMF was distilled from calcium hydride and stored over 3E molecular sieves. Azide AcGlc-N3 was prepared according to the procedures described in literature and its chemical and physical
properties were in agreement with previous data 34 .
General procedure for preparation of the glucopyranosyl amine (AcGlc-NH2).
After two vacuum/H2 cycles to remove air from the reaction tube, the stirred mixture of azide AcGlc-N3 (5.00 g, 13.4 mmol), 10% Pd/C (0.95 g) in ethyl acetate (EtOAc, 184.6 mL) was hydrogenated at ambient pressure (balloon) and temperature (ca. 20 o C) for 24 h. The reaction mixture was filtered and the filtrate was concentrated in vacuum. The residue was purified by flash column chromatography using EtOAc. The spectroscopic properties of amine AcGlc-NH2 were in agreement with previous data 35 . 
General procedure for preparation of the protected amides (AcS
N-(2,3,4,6-Tetra-O-acetyl-β-D-glucopyranosyl)-4(prop-1-enyl)biphenyl amide (AcS1
N-(2,3,4,6-Tetra-O-acetyl-β-D-glucopyranosyl)-6-butyl-1,2,3,4-tetrahydronapthalene amide (AcS2
N-(2,3,4,6-Tetra-O-acetyl-β-D-glucopyranosyl)-4-ethoxybiphenyl amide (AcS3).
Yellow foam, 55% yield; Rf = 0.33 (n-hexane/ 
N-(2,3,4,6-Tetra-O-acetyl-β-D-glucopyranosyl)-1-isopropyl-4(prop-1enyl)benzene amide (AcS6
N-(2,3,4,6-Tetra-O-acetyl-β-D-glucopyranosyl)-1-sec-butyl-4-ethylbenzene amide (AcS20
N-(2,3,4,6-Tetra-O-acetyl-β-D-glucopyranosyl)-1-isobutyl-4-isopropylbenzene (AcS21
General procedure for the preparation of unprotected nucleosides(S).
The protected nucleosides (AcS) (1 mmol) were treated with ammonia/MeOH (saturated at 0 °C, 41.8 mL)
overnight at room temperature. The solvent was evaporated under reduced pressure to afford pure S, in 66-81% yields as syrups. 
N-(β-D-Glucopyranosyl)-4(prop-1-enyl)biphenyl amide (S1
N-(β-D-Glucopyranosyl)-6-butyl-1,2,3,4-tetrahydronapthalene amide (S2
N-(β-D-Glucopyranosyl)-4-ethoxybiphenyl amide (S3
N-(β-D-Glucopyranosyl)-1-isopropyl-4(prop-1enyl)benzene amide (S6
N-(β-D-Glucopyranosyl)-1-sec-butyl-4-ethylbenzene amide (S20)
.
N-(β-D-Glucopyranosyl)-1-isobutyl-4-isopropylbenzene (S21
Protein purification and kinetic measurements
Rabbit skeletal muscle glycogen phosphorylase b was isolated, purified recrystallized and assayed as described previously 36 . Kinetic studies were performed at 30° C in the direction of glycogen synthesis by measuring the inorganic phosphate released in the reaction as reported previously 36 . The enzyme (5 µg/ml) was assayed in a buffer of 30 mM imidazole/HCl (pH 6.8) containing 60 mM KCl, 0.6 mM EDTA, and 0.6 mM dithiothreitol using constant concentrations of glycogen (0.2% w/v), AMP (1 mM), and various concentrations of Glc-1-P (2, 4, 6, 10 and 20 mM) and inhibitors. Enzyme and glycogen were preincubated for 15 min at 30°C before initiating the reaction with Glc-l-P. Initial velocities were calculated from the pseudo-first order rate constants. For the calculation and statistical evaluation of the kinetic and binding parameters, the non-linear regression program GRAFIT was used 37 .
Protein crystallography
Crystallographic binding studies were performed by diffusion of a solution of the C-5 halogen substituted glucopyranosyl nucleosides in the crystallization media of preformed GPb crystals. GPb crystals were grown in the tetragonal lattice, space group P43212, under conditions similar to those described previously 38 . These crystals were soaked in a 5 mM inhibitor solution in a buffer of 10 mM Sodium N,N-Bis(2-hydroxyethyl)-2-aminoethanesulfonic (pH 6.7) containing 0.1 mM EDTA, and 0.02 % w/v sodium azide at room temperature for 2 hours prior to data collection. X-ray diffraction data were collected using synchrotron radiation on station ID911-2 at MAX-Lab Synchrotron Radiation Source in Lund, Sweden or for the GPb-S6 complex on an Oxford Diffraction SuperNova X-ray system using a 135 mm CCD detector at room temperature. with codes presented in Table 6 .
Ex vivo experiments
Hepatocytes were isolated from male Wistar rats, 200-300g body wt (obtained from Harlan UK, Ltd) by collagenase perfusion 44 . Procedures conformed to Home Office Regulations and were approved by Newcastle University Ethical Committee. Hepatocytes were suspended in Minimum Essential Medium (MEM) with 5% calf serum and seeded in multi-well plates at a density of 6 x 10 4 cells / cm 2 . After cell attachment the medium was replaced by serum-free MEM containing 5 mM glucose, 10 nM dexamethasone, 1 nM insulin and the hepatocytes were cultured for 24 h. For determination of the effects of the GP inhibitors on conversion of GPa to GPb, the compounds or glucose (to a final concentration of 25 mM) were added to the medium 1 h after the change of medium and the incubations were continued for a further 30 min. Incubations with 5 mM or 25 mM glucose were also done in the additional presence of 5-thioglucose (9 mM), a hexokinase inhibitor, that prevents the elevation in glucose 6-P at 25 mM glucose 45 . The monolayers were snap frozen in liquid nitrogen and the activity of GPa was determined by coupling glycogen phosphorylase to the glucose 6-phosphate dehydrogenase reaction as described previously 45 . GPa activity in cells incubated with the GP inhibitors or with 25 mM glucose was expressed as percentage of the corresponding controls containing 5mM glucose (without or with 5-thioglucose). Results are Means ± SEM for 5 hepatocyte preparations. Statistical analysis was by the paired t-test.
Results
Virtual Screening
Training Set Results
To evaluate the performance of CombiGlide and GOLD with different scoring functions for the task at hand, a training set of ligands was employed with known inhibitory constants, each of these ligands containing a -NH-CO-group at the C1 anomeric position, but included ligands with extended linkers (e.g. -NHCONHCO-) so as to increase training set size as well as the spread of experimental binding affinities (Table S1 ).
The performances were evaluated with respect to the recovery of active molecules, which we defined as those with Ki's < 10 µM (10 ligands within a set of 40) and is reported in Table 2 .
Statistical performance metrics used were hit-rate, efficiency factor (EF), receiver operator characteristic (ROC) plots and (normalized) sum of the log ranks ((N)SLR), as described in the Experimental Section. Docking algorithms/scoring functions tested comprised Glide-SP and -XP; GOLD with -ChemScore, -ChemPLP, and -GoldScore and -ASP (two knowledgebased scoring functions). The best scoring functions were combined in a consensus scoring approach to ranking of ligand binding affinities 16 . Each of the six scoring functions has strengths and weaknesses. To increase the success rate in virtual screening, it may therefore be beneficial to use several scoring functions and apply "consensus scoring" for which a considerable reduction of false positives has previously been reported 16, 30 .
Although all scoring methods performed reasonably well, Glide-SP and GOLD-ChemPLP scores were found to be the most robust (Table 2) where the S represents Screening Set ligand and the N is the overall rank of the ligand with S1
Screening Set Results
having the best (lowest) Simple Sum Rank and S29 the worst (highest).
Prioritization of Ligands for Synthesis & Biological Evaluation
The final set of 29 ligands were clustered into groups based on 2D fingerprints (c.f. Experimental Section; Table S3 ). Criteria used to select ligands from the clusters were the Simple Sum Rank, coarse quantile votes 16 from the other scoring functions, and ADME properties (Tables 3 and S3) considering Lipinksi's 'rule of five' 32 and Jorgensen's 'rule of three' 33 . Ultimately, the six ligands shown in Table 1 were chosen due to availability and therefore synthetic viability. In terms of recovery of actives, 50% of the six molecules synthesized were found to be actives (Ki's < 10 µM as defined for by our initial training set).
Chemistry
The 
Biochemical assessment
To validate our synthesized compounds we tested their inhibitory potency on kinetics experiments with rabbit muscle glycogen phosphorylase b (GPb) in the direction of glycogen synthesis. Human liver GPb and rabbit muscle GPb active sites are identical in amino-acid sequence and structural architecture and hence active site ligands tested against rabbit muscle
GPb are expected to be potent against human liver glycogen phosphorylase as well. The inhibition constants are shown in Table 1 . All compounds displayed competitive inhibition with respect to the substrate Glc-1-P, at constant concentrations of glycogen and AMP. The most potent are compounds S1 (Ki=5.14 µM) and S6 (Ki=4.98 µM) followed closely by S3 (Ki=8.25 µM). From the inhibition constant values ( Table 1 ) it seems that compounds S2, S21
and S20 that have a certain degree of freedom in the linker that connects the Glc-NHCO group to the aromatic rings are worse inhibitors than those that have a linker with a more rigid geometry which directs the position of the phenyl rings.
Cellular evaluation
GP ligands that stabilise the T-state promote conversion of GPa to GPb in hepatocytes because the T-state is a better substrate for dephosphorylation by phosphorylase phosphatase, whereas compounds that stabilise the R-state have the converse effect and promote conversion of GPb to GPa 46 . We compared the effects of S1, S2, S3 and S6 with 25 mM glucose on depletion of GPa during a 30 min incubation of the hepatocytes (Table 4 ). The effects of 25 mM glucose were also tested in the presence of the hexokinase inhibitor, 5-thioglucose, to prevent the elevation in glucose 6-P caused by 25mM glucose. 45 Glucose (25 mM) lowered GPa by 36% in the absence of inhibitor and by 21% in the presence of the hexokinase inhibitor, in agreement with previous findings that glucose inactivates GPa through the combined effects of glucose and the elevated glucose 6-P 45 . S1 and S3 caused significant lowering of GPa at concentrations of 2 µM (11-15%) and at 20 µM (17-20%),
showing that these compounds mimic the effect of elevated glucose at low micromolar concentrations, and also that their effect is comparable to the inhibition caused by glucose in the presence of the hexokinase inhibitor. S2 and S6 had no significant effect (Table 4 ).
Structural studies
Towards elucidating the structural basis of inhibition and most importantly the differences in the inhibition constants, we have determined the crystal structures of the six selected inhibitors in complex with GPb. All inhibitors were found bound at the active site with their atoms well defined within the electron density maps (Fig. 1) . The anchor point for each of the inhibitors appears to be the glucose moiety which is engaged in hydrogen bond (Table 5 ) and van der Waals interactions almost identical to those that have observed for glucose and in other glucose containing inhibitors 1, 2, 10, 47 . Inhibitors S1 and S3 (the most potent) bind very similar with the R group in the β-pocket participating in van der Waals interactions with residues Glu88, Asn133, Tyr280, Asn282, Asp283, Phe286, Arg292, His341, and Glu385 (Fig 2) . The introduction of ether oxygen in the linker (S3) instead of methyl did not seem to affect the binding as this oxygen is not involved in any hydrogen bond interactions with protein residues in the vicinity (Fig 2) . Meanwhile the van der Waals interactions of this oxygen in the S3 complex are similar to those of the corresponding carbon in the S1 complex.
Inhibitors S6, S20 and S21 bind similar to each other, within the β-pocket, but remarkably different from S1 and S3. Their R groups are closer to the location of the 280s loop in the free GPb structure than S1 and S3. The distance between the benzene rings of S6, S20, and S21
are those of S1 and S3 is approximately 1.6, 1.8 and 2.6 Å in the respective complexes.
However, the methyl groups of S6, and S21, and the ethyl group of S20 on the benzyl group are all in the same location (within a radius of 0.5 Å) involved in similar van der Walls interactions with residues Tyr280, Asn282, Phe285, His341, and Ala383 (Fig 2) . The methyl group in the linkers of S20 and S21 point towards the same direction and participates in van der Waals interactions with side chain atoms of Leu136 and Asp339. Inhibitor S2 binds similarly to S1 but the linker follows a different route to place the tetrahydro-naphtalene group in the place where the two benzyl rings of S1 and S3 bind, participating in similar van der Waals interactions with protein residues. The differences in the conformation of the linker observed are probably imposed by the architecture of the β-pocket in the protein and its hydrophobic characteristics that attract the R group of all six inhibitors. Thus, since the R group is attracted at this location the linker is rearranged (according to its stereochemistry) to allow the binding.
All six inhibitors upon binding induce a significant conformational change of the 280s loop (residues 280-288) is observed when comparing the complex structures to the unliganded (Fig. 3) . Thus, it seems that the presence of the R group of the two inhibitors induces the movement of this loop away from the active site making space for the inhibitor. Thus the atoms from residues 282-287 upon superposition onto the corresponding ones of the unliganded GPb structure show an rms displacement of 1.5, 1.2, 2.0, 2.2, 1.2 and 2.2 Å for the S1, S2, S3, S6, S20 and S21 complexes, respectively. From the above values it is evident that S2 and S20 cause the smaller disturbance to the 280s loop. Comparing the conformational change of the 280s loop induced by the binding of the inhibitors it seems that S1, S2 and S20 trigger a mere displacement of the 280s loop while the rest of the inhibitors cause also more significant conformational changes. Briefly, in the S3, S6, and S21 complexes Asp283 and Asn284 shift away from the ligand to avoid clashes with the R group, with concomitant shifts of the other residues of the 280s loop. More specifically, Asn284 flips 180° and is positioned between the phenyl rings of Phe285 and Tyr613, two residues that constitute the inhibitor site at the entrance of the catalytic site in GPb, resulting in its disruption. This rearrangement of the 280s loop is in the direction of the R to T allosteric conversion and has been also observed in other GPb ligand complexes with bulky benzoyl moieties [48] [49] [50] .
Discussion and Conclusions
The structural studies offer an explanation for the differences in the inhibitory potency of the six inhibitors. Thus, since all six inhibitors are involved in the same hydrogen bond interactions (direct and water mediated) our attention shifted to the van der Waals interactions of the ligands. The virtual screening was performed with the goal to maximize the non-polar interactions of the R group within the β-pocket of the active site. The two most potent inhibitors S1 and S6 that display similar potency form the same number of van der Waals interactions with the protein (100) while the third best (S3) participates in slightly fewer (91) and thus has a slight increased Ki value. This pattern is repeated with the other two inhibitors, S2 and S21 that engage in 78 and 71 van der Waals interactions with the protein and have Ki values of 48.7 and 75.3 µM, respectively. The only exception to this pattern is S20 that forms 71 non-polar interactions like S21 but has a Ki value five times bigger than S21 ( Table 1 ). The main difference in the binding of these two inhibitors is the conformational change they induce on the 280s loop. Thus, the binding of S20 causes a more severe rearrangement of the loop than the one caused by the binding of S21. This is pronounced by the shifts of Asp283 and Asn284 described above, and this probably has energy cost that increases the Ki value of S20 with respect to that of S21.
A structural comparison with the GPb -N-4-phenylbenzoyl-2-N'-β-D-glycopyranosyl urea complex 49 (PDB id: 2qln), the inhibitor (Ki=3.7 µM ) used as a scaffold for modelling reveals that S1 and S3 bind very similar with this compound. However, both S1 and S3 lack the second carbonyl oxygen in the linker of the scaffold compound and thus are not involved in any of the additional water-mediated of the scaffold compound and Gly134, Gly135, Gly137, and Asp283. These interactions probably are responsible for the slightly better inhibitory potency of the scaffold compound with respect to S1 and S3. S1 and S3 are effective at causing inactivation of GPa in hepatocytes at low micromolar concentrations. The magnitude of the inhibition is smaller than for 25 mM glucose which is mediated in part through the raised concentration of glucose 6-P 45 , but it is comparable to the effect of 25 mM glucose in the presence of the hexokinase inhibitor which blocks glucose phosphorylation and the elevation in glucose 6-P.
The current synthetic scheme/combinatorial protocols were for glucose-NHCO-R ligands,
where by default the -R group was connected to the -NHCO-via a carbon. We now plan to extend our screening approach to glucose analogues with a more extended linker such as - Hepatocytes were incubated in MEM containing 5mM and the analogues indicated (at 2 or 20 µM) or with 25 mM glucose without or with hexokinase inhibitor (5-thioglucose). After 30 min, hepatocytes were snap frozen for determination of GPa in the cell extracts. GPa is expressed as percentage of the respective controls with 5 mM glucose without or with 9 mM 5-thioglucose. Means ± SEM (n=5).
* P < 0.05; ** P < 0.005, effect of analogue or 25 mM glucose relative to the respective control 
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